-
Today it is unveiling more data from that Phase III study, showing exactly how much Lucentis improved vision in AMD patients versus a placebo injection.
FORBES: Magazine Article
-
Recall that a few patients in the phase III study presented last fall at ACR also experienced heart failure, but that TNFs are also associated with heart failure.
FORBES: Pfizer's Key Drug Walks A Tightrope
-
In the first stage of a phase III study called CLL11, the drug in combination with chemotherapy significantly reduced the risk of disease worsening or death compared to chemotherapy alone in previously untreated patients.
FORBES: Roche's Worth $58 On Continued Growth And Strong Pipeline
-
These positive results help pave the way for the pivotal Phase III efficacy study that will recruit up to 16, 000 children and infants at 11 trial sites in seven countries.
WSJ: Defeat Malaria? Yes We Can.
-
"The most important trial we have is this phase-III single-agent study which compares daily Tarceva with best-supported care, " says Goddard.
FORBES: OSI Pharmaceuticals Defends Its Drug
-
BioSante reported that with 2, 869 women enrolled and over 3, 000 women-years of exposure in it LibiGel Phase III cardiovascular and breast cancer safety study, there have been 17 adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately 0.57 percent.
FORBES: BioSante's Pollyannish Press Release
-
Therefore, the Phase III LibiGel (testosterone gel) safety study will continue as per the FDA-agreed protocol, without modifications including continued enrollment of new subjects.
FORBES: BioSante's Pollyannish Press Release
-
This is unlikely to surprise some investors, but a new study has determined that advanced knowledge of Phase III clinical trials of new cancer meds and FDA decisions may affect the publicly traded shares prices of drugmakers.
FORBES: Why Pharma Stocks May Rise Before Trial Data Is Released
-
This study is actually the first of four placebo-controlled, Phase III trials to be completed.
FORBES: Pfizer And J&J Alzheimer's Drug Fails Late-Stage Trial